- Home
- EDD vs IMAB Comparison
EDD vs IMAB Comparison
Compare EDD & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- IMAB
- Stock Information
- Founded
- EDD 2007
- IMAB 2014
- Country
- EDD United States
- IMAB United States
- Employees
- EDD N/A
- IMAB N/A
- Industry
- EDD Finance Companies
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EDD Finance
- IMAB Health Care
- Exchange
- EDD Nasdaq
- IMAB Nasdaq
- Market Cap
- EDD 329.4M
- IMAB 394.2M
- IPO Year
- EDD N/A
- IMAB 2020
- Fundamental
- Price
- EDD $5.30
- IMAB $4.32
- Analyst Decision
- EDD
- IMAB Strong Buy
- Analyst Count
- EDD 0
- IMAB 6
- Target Price
- EDD N/A
- IMAB $7.17
- AVG Volume (30 Days)
- EDD 254.3K
- IMAB 1.6M
- Earning Date
- EDD 01-01-0001
- IMAB 11-02-2025
- Dividend Yield
- EDD 7.52%
- IMAB N/A
- EPS Growth
- EDD N/A
- IMAB N/A
- EPS
- EDD N/A
- IMAB N/A
- Revenue
- EDD N/A
- IMAB N/A
- Revenue This Year
- EDD N/A
- IMAB N/A
- Revenue Next Year
- EDD N/A
- IMAB N/A
- P/E Ratio
- EDD N/A
- IMAB N/A
- Revenue Growth
- EDD N/A
- IMAB N/A
- 52 Week Low
- EDD $4.22
- IMAB $0.60
- 52 Week High
- EDD $4.95
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- EDD 39.65
- IMAB 58.60
- Support Level
- EDD $5.47
- IMAB $3.40
- Resistance Level
- EDD $5.69
- IMAB $4.02
- Average True Range (ATR)
- EDD 0.08
- IMAB 0.29
- MACD
- EDD -0.04
- IMAB 0.04
- Stochastic Oscillator
- EDD 10.95
- IMAB 82.88
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).